

FILE 'HOME' ENTERED AT 12:43:37 ON 14 JUL 2005

L1 206 (HPV OR PAPILLOMA?) AND (PDZ OR DLG OR MAGUK OR MAGI### OR MEMBR
ANE (A) ASSOCIATED (A) GUANYLATE (A) KINASE (A) INTERACTING (A)
PROTEIN?)

L2 176 L1 AND "E6" (P) (PDZ OR DLG OR MAGUK OR MAGI### OR MEMBR ANE
(A) ASSOCIATED (A) GUANYLATE (A) KINASE (A) INTERACTING (A)
PROTEIN?)

L3 44 L1 AND "E6" (S) PDZ (P) (MAGI### OR MEMBRANE (A) ASSOCIATED (A)
GUANYLATE (A) KINASE (A) INTERACTING (A) PROTEIN?)

(FILE 'HOME' ENTERED AT 12:43:37 ON 14 JUL 2005)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, CANCERLIT' ENTERED AT
12:44:14 ON 14 JUL 2005

L1 206 S (HPV OR PAPILLOMA?) AND (PDZ OR DLG OR MAGUK OR MAGI### OR ME
L2 176 S L1 AND "E6" (P) (PDZ OR DLG OR MAGUK OR MAGI### OR MEMBR
L3 44 S L1 AND "E6" (S) PDZ (P) (MAGI### OR MEMBRANE (A) ASSOCIATED (
L4 104 S L2 AND PY<2003
L5 23 S L4 AND L3
L6 4 DUP REM L5 (19 DUPLICATES REMOVED)
L7 23 DUP REM L4 (81 DUPLICATES REMOVED)
L8 19 S L7 NOT L6

L6 ANSWER 1 OF 4 MEDLINE on STN DUPLICATE 1
 AN 2002683177 MEDLINE
 DN PubMed ID: 12444549
 TI Chimaeric **HPV E6** proteins allow dissection of the proteolytic pathways regulating different **E6** cellular target proteins.
 AU Pim David; Thomas Miranda; Banks Lawrence
 CS International Centre for Genetic Engineering and Biotechnology, Area Science Park, Padriciano-99, I-34012, Trieste, Italy.. pim@icgeb.org.it
 SO Oncogene, (2002 Nov 21) 21 (53) 8140-8.
 Journal code: 8711562. ISSN: 0950-9232.
 CY England: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200212
 ED Entered STN: 20021122
 Last Updated on STN: 20021227
 Entered Medline: 20021223
 AB The ability of **HPV E6** oncoproteins to induce the degradation of **PDZ** domain-containing **MAGUK** proteins correlates with their malignant potential. We previously showed that the **HPV-6 E6** protein, when provided with the **PDZ**-binding domain from **HPV-18 E6**, acquires the ability to bind the Discs Large (**Dlg**) tumour suppressor and target it for degradation. Based on this finding we have extended this analysis to **E6** proteins from a variety of different **papillomavirus** types. Cloning a **PDZ**-binding sequence onto the C-terminus of **E6** proteins derived from low-risk mucosal, and low and high-risk cutaneous **papillomavirus** types, enables them to bind **Dlg** and a second **MAGUK** family member, **MAGI-1**. This renders the mucosally-derived low-risk chimaeric **HPV E6** proteins capable of targeting **Dlg** for degradation, but they are unable to induce significant levels of degradation of **MAGI-1**. In contrast, none of the **E6** proteins derived from cutaneous **papillomavirus** types induce significant degradation of either **MAGI-1** or **Dlg** when provided with a **PDZ**-binding domain. These results demonstrate significant differences, both between mucosal and cutaneous **HPV E6** proteins and in the pathways required for **Dlg** and **MAGI-1** degradation.

L6 ANSWER 2 OF 4 MEDLINE on STN DUPLICATE 2
 AN 2002392026 MEDLINE
 DN PubMed ID: 12140759
 TI Oncogenic human **papillomavirus E6** proteins target the **MAGI-2** and **MAGI-3** proteins for degradation.
 AU Thomas Miranda; Laura Richard; Hepner Karin; Guccione Ernesto; Sawyers Charles; Lasky Laurence; Banks Lawrence
 CS International Centre for Genetic Engineering and Biotechnology, Padriciano 99, 34012 Trieste, Italy.
 SO Oncogene, (2002 Aug 1) 21 (33) 5088-96.
 Journal code: 8711562. ISSN: 0950-9232.
 CY England: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200208
 ED Entered STN: 20020726
 Last Updated on STN: 20020904
 Entered Medline: 20020816
 AB The **E6** proteins from the high-risk human **papillomavirus** (**HPV**) types have previously been shown to target a number of **PDZ** domain-containing proteins for proteasome-mediated degradation. These include the h**Dlg** tumour suppressor and the **MAGI-1** protein. In this study we show that high-risk **HPV E6** proteins also target the related **MAGI-2** and **MAGI-3** proteins for degradation. Moreover, we show that the interaction is specific to one **PDZ** domain, and that

co-expression of this domain can protect each of the full-length **MAGI** proteins from **E6**-mediated degradation. These data provide clear indicators for the potential design of compounds that could specifically inhibit the interaction of oncogenic **HPV E6** proteins with an important class of target proteins.

L6 ANSWER 3 OF 4 MEDLINE on STN DUPLICATE 3
AN 2001522961 MEDLINE
DN PubMed ID: 11571640
TI **HPV E6** and **MAGUK** protein interactions:
determination of the molecular basis for specific protein recognition and degradation.
AU Thomas M; Glaunsinger B; Pim D; Javier R; Banks L
CS International Centre for Genetic Engineering and Biotechnology, Padriciano 99, I-34012 Trieste, Italy.
NC R01 CA58541 (NCI)
SO Oncogene, (2001 Sep 6) 20 (39) 5431-9.
Journal code: 8711562. ISSN: 0950-9232.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200110
ED Entered STN: 20010926
Last Updated on STN: 20011015
Entered Medline: 20011011
AB It has recently been shown that the high-risk human **papillomavirus** (**HPV**) **E6** proteins can target the **PDZ**-domain containing proteins, **Dlg**, **MUPP-1**, **MAGI-1** and **hScrib** for proteasome-mediated degradation. However, the **E6** proteins from **HPV-16** and **HPV-18** (the two most common high-risk virus types) differ in their ability to target these proteins in a manner that correlates with their malignant potential. To investigate the underlying mechanisms for this, we have mutated **HPV-16** and **HPV-18 E6s** to give each protein the other's **PDZ**-binding motif. Analysis of these mutants shows that the greater ability of **HPV-18 E6** to bind to these proteins and to target them for degradation is indeed due to a single amino acid difference. Using a number of assays, we show that the **E6** proteins interact specifically with only one of the five **PDZ** domains of **MAGI-1**, and this is the first interaction described for this particular **PDZ** domain. We also show that the guanylate kinase homology domain and the regions of **MAGI-1** downstream of amino acid 733 are not required for the degradation of **MAGI-1**. Finally, in a series of comparative analyses, we show that the degradation of **MAGI-1** occurs through a different mechanism from that used by the **E6** protein to induce the degradation of **Dlg** and **p53**.

L6 ANSWER 4 OF 4 MEDLINE on STN DUPLICATE 4
AN 2001029726 MEDLINE
DN PubMed ID: 11077444
TI Interactions of the **PDZ**-protein **MAGI-1** with adenovirus **E4-ORF1** and high-risk **papillomavirus E6** oncoproteins.
AU Glaunsinger B A; Lee S S; Thomas M; Banks L; Javier R
CS Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA.
NC R01CA58541 (NCI)
T32AI07471 (NIAID)
SO Oncogene, (2000 Nov 2) 19 (46) 5270-80.
Journal code: 8711562. ISSN: 0950-9232.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200011
ED Entered STN: 20010322
Last Updated on STN: 20010322

Entered Medline: 20001121

AB The oncoproteins of small DNA tumor viruses promote tumorigenesis by complexing with cellular factors intimately involved in the control of cell proliferation. The major oncogenic determinants for human adenovirus type 9 (Ad9) and high-risk human **papillomaviruses (HPV)** are the E4-ORF1 and **E6** proteins, respectively. These seemingly unrelated viral oncoproteins are similar in that their transforming activities in cells depend, in part, on a carboxyl-terminal **PDZ** domain-binding motif which mediates interactions with the cellular **PDZ**-protein **DLG**. Here we demonstrated that both Ad9 E4-ORF1 and high-risk **HPV E6** proteins also bind to the **DLG**-related **PDZ**-protein **MAGI-1**. These interactions resulted in **MAGI-1** being aberrantly sequestered in the cytoplasm by the Ad9 E4-ORF1 protein or being targeted for degradation by high-risk **HPV E6** proteins. Transformation-defective mutant viral proteins, however, were deficient for these activities. Our findings indicate that **MAGI-1** is a member of a select group of cellular **PDZ** proteins targeted by both adenovirus E4-ORF1 and high-risk **HPV E6** proteins and, in addition, suggest that the tumorigenic potentials of these viral oncoproteins depend, in part, on an ability to inhibit the function of **MAGI-1** in cells.

L4 ANSWER 2 OF 104 MEDLINE on STN
AN 2002683177 MEDLINE
DN PubMed ID: 12444549
TI Chimaeric **HPV** E6 proteins allow dissection of the proteolytic pathways regulating different E6 cellular target proteins.
AU Pim David; Thomas Miranda; Banks Lawrence
CS International Centre for Genetic Engineering and Biotechnology, Area Science Park, Padriciano-99, I-34012, Trieste, Italy.. pim@icgeb.org.it
SO Oncogene, (2002 Nov 21) 21 (53) 8140-8.
Journal code: 8711562. ISSN: 0950-9232.

L4 ANSWER 3 OF 104 MEDLINE on STN
AN 2002413711 MEDLINE
DN PubMed ID: 12167343
TI Cellular steady-state levels of "high risk" but not "low risk" human **papillomavirus (HPV)** E6 proteins are increased by inhibition of proteasome-dependent degradation independent of their p53- and E6AP-binding capabilities.
AU Kehmeier Eva; Ruhl Heiko; Volland Britta; Stoppler Melissa Conrad; Androphy Elliot; Stoppler Hubert
CS Department of Pharmacology and Toxicology, Philipps University Marburg, Karl-von-Frisch Strasse 1, D-35033, Germany.
SO Virology, (2002 Jul 20) 299 (1) 72-87.
Journal code: 0110674. ISSN: 0042-6822.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200211
ED Entered STN: 20020809
Last Updated on STN: 20030304
Entered Medline: 20021106
AB The group of mucosal epithelia-infecting human **papillomaviruses (HPV)** can be subdivided in "low" and "high risk" **HPV** types. Both types induce benign neoplasia (condyloma), but only the infection with a "high risk" **HPV** type is causally associated with an increased risk of developing anogenital tumors. The oncogenic potential of high risk **HPVs** resides at least partially in the viral **E6** protein. The **E6** protein targets the cellular p53 protein for proteasome-dependent degradation, which is associated with the immortalizing and transforming functions of these viruses. Recently the **E6**-dependent proteasome-mediated destabilization of additional cellular proteins (E6TP1, c-myc, Bak, hMCM7, human scribble, E6AP, **MAGI-1**) has been described, but the cellular mechanisms controlling the viral **E6** protein stability itself have been so far not analyzed. In this study, we transiently expressed the **E6** genes of the high risk **HPV** type 16, the low risk **HPV** types 6a and 11, and the cutaneous epithelia-infecting **HPV** types 5 and 8 from a eucaryotic expression vector and compared the cellular steady-state levels of the expressed **E6** proteins. We demonstrated that the high risk **HPV** 16 **E6** protein possesses the lowest steady-state level in comparison to the low risk **HPV** type **E6** proteins and the cutaneous epithelia-infecting **HPV** type **E6** proteins. Inhibition of cellular proteasome-dependent protein degradation led to an increase in steady-state levels of high risk but not of low risk **E6** proteins. Analysis of functionally deficient **HPV** 16 **E6** proteins in p53 null- and p53 wild-type-expressing cell lines revealed that the cellular steady-state level of this protein is influenced neither by its p53- nor its E6AP-binding abilities.

L4 ANSWER 16 OF 104 MEDLINE on STN
AN 97471015 MEDLINE
DN PubMed ID: 9326658
TI Binding of high-risk human **papillomavirus** E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein.
AU Kiyono T; Hiraiwa A; Fujita M; Hayashi Y; Akiyama T; Ishibashi M

CS Laboratory of Viral Oncology, Aichi Cancer Center, Research Institute, 1-1
Kanokoden, Chikusa-ku, Nagoya 464, Japan.

SO Proceedings of the National Academy of Sciences of the United States of
America, (1997 Oct 14) 94 (21) 11612-6.
Journal code: 7505876. ISSN: 0027-8424.

L8 ANSWER 3 OF 19 MEDLINE on STN
AN 2002110761 MEDLINE
DN PubMed ID: 11807220
TI Mutational analysis of the discs large tumour suppressor identifies
domains responsible for human **papillomavirus** type 18 E6-mediated
degradation.

AU Gardiol Daniela; Galizzi Silvina; Banks Lawrence
CS Instituto de Biologia Molecular y Celular de Rosario (IBR-CONICET),
Departamento de Microbiologia, Facultad de Ciencias Bioquimicas, Suipacha
531, 2000 Rosario, Argentina.. dgardiol@fbioyf.unr.edu.ar
SO Journal of general virology, (2002 Feb) 83 (Pt 2) 283-9.
Journal code: 0077340. ISSN: 0022-1317.

CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200203
ED Entered STN: 20020215
Last Updated on STN: 20020308
Entered Medline: 20020307

AB The discs large (**Dlg**) tumour suppressor protein is targeted for
ubiquitin-mediated degradation by the high-risk human
papillomavirus E6 proteins. To understand further the
mechanisms behind this, a mutational analysis of **Dlg** was
undertaken. This study demonstrates that an intact **PDZ** domain 2
(PDZ2) on **Dlg** is necessary for the ability of **E6** to
bind and degrade **Dlg**. However, additional residues within the
amino-terminal portion of **Dlg** are also required for optimal
E6 activity. Stable cell lines expressing different **Dlg**
mutants were also established and these confirm that **Dlg** is
regulated intrinsically by the proteasome in the absence of **E6**;
however, in this case, the sequences responsible for regulating
Dlg stability lie predominantly within PDZ2. These results
suggest that there are at least two mechanisms for regulating **Dlg**
protein stability and that the pathways used by **E6** are not
necessarily the same as those used in the cell in its absence.

L8 ANSWER 10 OF 19 MEDLINE on STN
AN 2000162315 MEDLINE
DN PubMed ID: 10698489
TI **HPV** E6 targeted degradation of the discs large protein: evidence
for the involvement of a novel ubiquitin ligase.

AU Pim D; Thomas M; Javier R; Gardiol D; Banks L
CS International Centre for Genetic Engineering and Biotechnology, Trieste,
Italy.
NC ROI CA58541 (NCI)
SO Oncogene, (2000 Feb 10) 19 (6) 719-25.
Journal code: 8711562. ISSN: 0950-9232.

L8 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:131285 CAPLUS
DN 128:165635
TI Binding of viral oncogenic proteins and **PDZ** domains of cellular
proteins

AU Hiraiwa, Atsuro; Ishibashi, Masahide
CS Sch. Med., Nagoya Univ., Nagoya, 466-8550, Japan
SO Tanpakushitsu Kakusan Koso (1998), 43(3), 237-243
CODEN: TAKKAJ; ISSN: 0039-9450
PB Kyoritsu Shuppan
DT Journal; General Review
LA Japanese

AB A review with 24 refs. on binding of human **papillomavirus**
E6 protein with the **PDZ** domain of hDLG (human homolog of
Drosophila disks, large tumor suppressor protein) in relation to
transforming activity. Binding of hDLG with E4ORF1 protein of adenovirus
or Tax protein of HTLV-1 is also described.

WEST Search History

[Hide Items](#)
[Restore](#)
[Clear](#)
[Cancel](#)

DATE: Thursday, July 14, 2005

Hide?	<u>Set</u> <u>Name</u>	<u>Query</u>	<u>Hit</u> <u>Count</u>
		<i>DB=USPT; PLUR=YES; OP=OR</i>	
<input type="checkbox"/>	L18	2000	41
<input type="checkbox"/>	L17	L14 and isolated with (protein or \$peptide) same (assay or method or screen\$)	298
<input type="checkbox"/>	L16	L14 and isolated with (protein or \$peptide)	360
<input type="checkbox"/>	L15	L14 and L13	57
<input type="checkbox"/>	L14	(screen\$ or identif\$) with (inhibit\$ or drug or antagon\$) same (peptide-peptide or protein-protein) near4 (interact\$ or binding)	442
<input type="checkbox"/>	L13	L12	523
		<i>DB=PGPB,USPT,EPAB,JPAB,DWPI; PLUR=YES; OP=OR</i>	
<input type="checkbox"/>	L12	2000	548
<input type="checkbox"/>	L11	L10 and (inhibit\$ or drug or antagon\$) near6 (interact\$ or binding)	8487
<input type="checkbox"/>	L10	(peptide-peptide or protein-protein) near4 (interact\$ or binding) and (screen\$ or identif\$) with (inhibit\$ or drug or antagon\$)	9531
<input type="checkbox"/>	L4	l1 and l2	122
<input type="checkbox"/>	L3	l1 and l2L2	0
<input type="checkbox"/>	L2	(peptide-peptide or protein-protein) near4 (interact\$ or binding)	12277
<input type="checkbox"/>	L1	drug adj screening same (cellular or cell-based or cell adj based) near4 assay	921

END OF SEARCH HISTORY



WEST Search History

[Hide Items](#)[Restore](#)[Clear](#)[Cancel](#)

DATE: Thursday, July 14, 2005

Hide?	<u>Set</u> <u>Name</u>	<u>Query</u>	<u>Hit</u> <u>Count</u>
		<i>DB=PGPB,USPT,EPAB,JPAB,DWPI; PLUR=YES; OP=OR</i>	
<input type="checkbox"/>	L5	l1 and (HPV or papillom\$ or HPV) same (MAGI-1 or MAGUK or membrane adj associated adj guanylate adj kinase adj interacting near3 1)	6
<input type="checkbox"/>	L4	L3 and l2	11
<input type="checkbox"/>	L3	l1 and (MAGI-1 or MAGUK or membrane adj associated adj guanylate adj kinase adj interacting near3 1)	28
<input type="checkbox"/>	L2	(papillomavir\$ or HPV or E6) same (PDZ or DLG or MAGI-1 or MAGUK or membrane adj associated adj guanylate adj kinase adj interacting near3 1)	20
<input type="checkbox"/>	L1	(papillomavir\$ or HPV or E6) and (PDZ or DLG or MAGI-1 or MAGUK or membrane adj associated adj guanylate adj kinase adj interacting near3 1)	126

END OF SEARCH HISTORY



All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for [] Preview Go Clear

Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

Special Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

- Search History will be lost after eight hours of inactivity.
- To combine searches use # before search number, e.g., #2 AND #6.
- Search numbers may not be continuous; all searches are represented.
- Click on query # to add to strategy

Search

Most Recent Queries

#8 Search MAGI* AND (HPV or E6)

#7 Search MAGI* AND (HPV or E;)

Time Result

13:09:53 15

13:09:43 547

Clear History

Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer

Jun 27 2005 04:57:20